Both Donanemab and Lecanemab slow the progression of Alzheimer's disease. Donanemab slowed the progression by about 4.5 to 7.5 months and Lecanemab slow the progression of the disease by about 5 to 6 months in an 18 month study. The drugs continued to have a benefit beyond 18 months as well. In general, patients receiving the IV medication are not transitioning as fast from one stage of Alzheimer’s disease to the next stage. It’s important to note that these medications are not preventative treatments nor a cure for Alzheimer’s disease.

To learn more about Alzheimer’s disease treatment and care at UCLA, please speak with your primary care doctor or call the UCLA Neurology Outpatient Clinic: 310-794-1195. You can also visit our website to find a provider, schedule an appointment, and learn more about treatment and care options: [ Ссылка ]

свернуть